CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture and industrial chemicals, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

Moderna is biotechnology company focused on the development of mRNA medicines. Through the advancement of its mRNA technology platform, Moderna is exploring new approaches to how medicines are made, with the aim of improving prevention and treatment of diseases. Since its founding, Moderna's mRNA platform has supported the research and development of vaccines and therapeutics across infectious diseases, cancer and rare diseases. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.

Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high-quality pre-clinical candidates for novel human therapeutics. With a team of experts who bring decades of scientific and commercial expertise, BioCurate provides a critical bridge between academia and industry to grow the Victorian and Australian biotech sector by increasing the number, quality, and rate of translation of new drug discoveries into medically sound and commercially attractive, investable projects.

Contact the host of Innovation 2 Translation 2026: What Shapes the Path to Translation?